Sunovion To Purchase Elevation And Phase II Drug/Device Combo For COPD
This article was originally published in The Pink Sheet Daily
Executive Summary
Earlier than anticipated exit for Elevation means less dilution for its venture capital backers, who had provided $30 million in Series B funds this past January.
You may also be interested in...
Start-Up Quarterly Statistics, Q3 2012
In the third quarter of 2012, start-up companies raised a total of $682 million across all industries, roughly 19% more than in the previous quarter. Of that money, 65% went to biopharmas. Several large molecule-focused companies inked deals during Q3. Four start-ups were acquired – three biopharmas and one medical device company.
With $30 Million Series B In Hand, Elevation Prepares To Take Inhalable COPD Drug Up To Phase III
The two-tranche financing, backed 50% by new investor Novo Ventures, will enable the private firm to evaluate early partnering opportunities from a position of financial stability.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.